COMPLERA
Peakemtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate
NDAORALTABLETPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
28
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Clinical Trials (5)
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Started Mar 2026
3,000 enrolled
HIV Infections
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Started Nov 2023
253 enrolled
Pre-Exposure Prophylaxis of HIV Infection
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Started Apr 2019
26 enrolled
HIV/AIDSAntiviral ToxicityAntiviral Drug Adverse Reaction+1 more
Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women
Started Jan 2017
1,000 enrolled
HIV Prevention
Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide
Started Oct 2016
80 enrolled
Renal Insufficiency,ChronicHivTherapeutic Agent Toxicity
Loss of Exclusivity
LOE Date
Jan 14, 2033
83 months away
Patent Expiry
Jan 14, 2033
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10857102 | Jan 14, 2033 | Product | — |